Recombinant Human CXCL4/PF4 (Mammalian-expressed), CF

Recombinant Human CXCL4/PF4 (Catalog # 7989-P4/CF) inhibits FGF basic-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is1-6 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CXCL4/PF4 (Mammalian-expressed), CF Summary

• Details of Functionality: Measured by its ability to inhibit the FGF basic-dependent proliferation of HUVEC human umbilical vein endothelial cells. Dubrac, A. et al. (2010) Blood 116:4703. The ED₅₀ for this effect is typically 1-6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CXCL4/PF4 protein
  Glu32-Ser101
• Accession #: P02776
• N-terminal Sequence: Glu32
• Protein/Peptide Type: Recombinant Proteins
• Gene: PF4
• Purity: >95%, by SDS-PAGE with silver staining.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 7.8 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 9-11 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE with silver staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CXCL4/PF4 (Mammalian-expressed), CF

• chemokine (C-X-C motif) ligand 4
• C-X-C motif chemokine 4
• CXCL4
• CXCL4iroplact
• Iroplact
• MGC138298
• Oncostatin-A
• PF4
• PF-4
• platelet factor 4
• SCYB4oncostatin-A

Background

CXCL4, also called PF4 (platelet factor 4), is an 8 kDa member of the CXC chemokine family, sharing features with CXCL8/IL‑8 and CXCL7/NAP‑2 (1‑3). Mature human CXCL4 shares 65‑76% amino acid sequence identity with mouse, rat, bovine, ovine and porcine CXCL4. The active protein is a tetramer of CXCL4 subunits that forms a ring of heparin-binding positive charges from sites at the C‑terminal region of each monomer (3). Megakaryocytes synthesize CXCL4 and store it in platelet alpha ‑granules (2, 3). Secretion from activated platelets can produce micromolar levels in serum and over 100‑fold higher within clots (2, 3). In contrast to other CXC chemokines, CXCL4 does not contain an ELR motif and lacks binding to nearly all chemokine receptors (2, 3). A potential high‑affinity G‑protein-coupled receptor for CXCL4, the CXCR3 isoform CXCR3B, is expressed in human but not mouse (2, 3). In most cases, it is likely that cell surface binding and signaling properties of CXCL4 are due to binding of glycosaminoglycans chains, particularly chondroitin sulfates (2). CXCL4 released from activated platelets binds and regulates thrombin/thrombomodulin complexes, regulates and enhances production of activated Protein C (APC), and limits the coagulation cascade (2‑6). It binds and influences the enzymatic activity of coagulation factor Xa (7). It binds fibrin and affects clot structure (8). Therapeutic doses of the anticoagulant heparin neutralize CXCL4 procoagulant effects (9). The complex between heparin and CXCL4 can be immunogenic, and circulating CXCL4‑heparin antibodies cause the pathological syndrome HITT (heparin-induced thrombocytopenia and thrombosis, also called HIT) (2). In addition, immunogenic complexes of CXCL4 with apolipoprotein H can contribute to antiphospholipid syndrome (APS) (10). CXCL4 can be antiproliferative and antiangiogenic, at least in part via interfering with FGF‑2 and VEGF heparin binding and thus inhibiting their signaling (3, 11‑13). However, it can also be proinflammatory and pro‑atherogenic through multiple effects on monocytes, macrophages and endothelial cells (2, 3).

1. Poncz, M. et al. (1987) Blood 69:219.
2. Kowalska, M.A. et al. (2010) Thromb. Res. 125:292.
3. Slungaard, A. (2005) Int. J. Biochem. Cell Biol. 37:1162.
4. Slungaard, A. et al. (2003) Blood 102:146.
5. Kowalska, M.A. et al. (2007) Blood 110:1903.
6. Preston, R.J.S. et al. (2009) J. Biol. Chem. 284:5869.
7. Fiore, M.M. and I.J. Mackie (2009) Biochem. Biophys. Res. Commun. 379:1072.
8. Amelot, A.A. et al. (2007) J. Biol. Chem. 282:710.
9. Eslin, D.E. et al. (2004) Blood 104:3173.
10. Sikara, M.P. et al. (2010) Blood 115:713.
11. Perollet, C. et al. (1998) Blood 91:3289.
12. Gengrinovitch, S. et al. (1995) Journal of Biological Chemistry 270:15059.
13. Sulpice, E. et al. (2004) Eur. J. Biochem. 271:3310.

Bioinformatics

• Gene Symbol: PF4
• Uniprot:
  • P02776()